| 何文君,孙 银,陈思瑶,徐智威,周季家,陈 丹.活血利水方对糖尿病性黄斑水肿患者视力功能、黄斑厚度、血清及玻璃体液HIF-1α、sICAM-1表达的影响[J].现代生物医学进展英文版,2024,(10):1969-1973. |
| 活血利水方对糖尿病性黄斑水肿患者视力功能、黄斑厚度、血清及玻璃体液HIF-1α、sICAM-1表达的影响 |
| Effect of Huoxue Lishui Decoction on Visual Function, Macular Thickness, Serum and Vitreous Fluid HIF-1α, sICAM-1 Expression in Patients with Diabetic Macular Edema |
| Received:October 24, 2023 Revised:November 20, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.10.035 |
| 中文关键词: 活血利水方 糖尿病性黄斑水肿 视力功能 黄斑厚度 HIF-1α sICAM-1 |
| 英文关键词: Huoxue Lishui Decoction Diabetic macular edema Visual function Macular thickness HIF-1 sICAM-1 |
| 基金项目:四川省中医药管理局科学技术研究专项课题（2020ZD0407） |
|
| Hits: 208 |
| Download times: 182 |
| 中文摘要: |
| 摘要 目的：探讨活血利水方对糖尿病性黄斑水肿（DME）患者视力功能、黄斑厚度、血清及玻璃体液低氧诱导因子1α（HIF-1α）、可溶性细胞间黏附分子1（sICAM-1）表达的影响，以期为DME优化治疗方案提供参考依据。方法：选取川北医学院附属遂宁市中医院和攀枝花中西医结合医院2022年6月～2023年6月80例DME患者为研究对象，随机抽签法随机分为对照组和观察组，各40例，对照组采用康柏西普治疗，观察组在对照组基础上联合活血利水方治疗。比较两组中医证候积分、临床疗效、最佳矫正视力（BCVA）、黄斑中心凹厚度（CFT）、血清及玻璃体液HIF-1α、sICAM-1表达、毒副反应发生率。结果：治疗后两组中医证候积分低于治疗前，且观察组低于对照组（P＜0.05）。观察组总有效率较对照组高（P＜0.05）。治疗后两组BCVA高于治疗前，且观察组高于对照组（P＜0.05）；治疗后两组CFT低于治疗前，且观察组低于对照组（P＜0.05）。治疗后两组血清及玻璃体液HIF-1α、sICAM-1水平低于治疗前，且观察组低于对照组（P＜0.05）。两组毒副反应发生率比较差异无统计学意义（P＞0.05）。结论：活血利水方辅助治疗DME患者效果确切，可降低中医证候积分，提高患眼视力，减轻黄斑水肿，抑制血清及玻璃体液HIF-1α、sICAM-1水平，且安全性高。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Huoxue Lishui Decoction on visual function, macular thickness, expression of hypoxia-inducible factor-1α(HIF-1α) and soluble intercellular adhesion molecule-1 (sICAM-1) in serum and vitreous fluid in patients with diabetic macular edema (DME), so as to provide reference for optimizing the treatment of DME. Methods: 80 patients with DME from June 2022 to June 2023 in Suining Traditional Chinese Medicine Hospital Affiliated to North Sichuan Medical College and Panzhihua Integrated Traditional Chinese and Western Medicine Hospital were randomly divided into control group and observation group, 40 cases in each group. The control group was treated with conbercept, and the observation group was treated with Huoxue Lishui Decoction on the basis of the control group. The TCM syndrome scores, clinical efficacy, best corrected visual acuity (BCVA), central foveal thickness (CFT), serum and vitreous fluid HIF-1α, sICAM-1 expression, and incidence of toxic and side effects were compared between the two groups. Results: After treatment, the scores of TCM syndromes in the two groups were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). The total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the BCVA of the two groups was higher than that before treatment, and that of the observation group was higher than that of the control group (P<0.05). After treatment, the CFT of the two groups was lower than that before treatment, and that of the observation group was lower than the control group (P<0.05). After treatment, the levels of serum and vitreous fluid HIF-1α and sICAM-1 in the two groups were lower than those before treatment, and those in the observation group were lower than the control group(P<0.05). There was no significant difference in the incidence of toxic and side effects between the two groups (P>0.05). Conclusion: Huoxue Lishui Decoction is effective in the adjuvant treatment of DME patients. It can reduce the TCM syndrome score, improve the visual acuity of the affected eye, reduce macular edema, inhibit the levels of HIF-1α and sICAM-1 in serum and vitreous fluid, and has high safety. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
